What does Cellectar Biosciences, Inc. do?
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study…
What is Cellectar Biosciences, Inc.'s P/E and P/B ratio?
Cellectar Biosciences, Inc. has a P/E ratio of -0.4 and a P/B ratio of 0.39.
What is Cellectar Biosciences, Inc.'s debt-to-equity ratio?
Cellectar Biosciences, Inc. has a debt-to-equity ratio of 0.05.
How much does Cellectar Biosciences, Inc. owe compared with what it owns?
Cellectar Biosciences, Inc. owes $0.18 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Cellectar Biosciences, Inc.'s Positivity rank?
Cellectar Biosciences, Inc. is ranked #1,662 of 6,775 companies globally and #378 of 3,999 in United States on PositoAI, with a Positivity Score of 22,528.
Does Cellectar Biosciences, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Cellectar Biosciences, Inc..
Where can I read the latest news about Cellectar Biosciences, Inc.?
Recent headlines about Cellectar Biosciences, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Cellectar Biosciences, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Cellectar Biosciences, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.